U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712380) titled 'A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events' on July 14.
Brief Summary: This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in adult individuals at risk for cardiovascular events.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Cardiovascular Disease
Intervention:
COMBINATION_PRODUCT: Placebo
Placebo will be administered intr...